You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Bulk Pharmaceutical API Sources for PROZAC WEEKLY


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for PROZAC WEEKLY

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial F132_SIGMA ⤷  Start Trial
Molport ⤷  Start Trial MolPort-003-666-535 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-1697 ⤷  Start Trial
TCI (Tokyo Chemical Industry) ⤷  Start Trial F0750 ⤷  Start Trial
Amadis Chemical ⤷  Start Trial A8349 ⤷  Start Trial
Amadis Chemical ⤷  Start Trial A830990 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: PROZAC WEEKLY

Last updated: July 30, 2025


Introduction

Prozac Weekly, the extended-release formulation of fluoxetine, is a widely prescribed antidepressant used in the management of major depressive disorder, obsessive-compulsive disorder, and bulimia nervosa. As a vital component in pharmaceutical manufacturing, the source of its active pharmaceutical ingredient (API)—fluoxetine hydrochloride—is crucial for quality, compliance, and supply chain integrity. This article examines the global landscape of bulk API sourcing for Prozac Weekly, offering insights into key manufacturers, procurement considerations, and industry trends.


Understanding the API: Fluoxetine Hydrochloride

Fluoxetine, the active compound in Prozac Weekly, is a selective serotonin reuptake inhibitor (SSRI). The API's quality directly influences the drug's safety and efficacy. Pharmaceutical companies typically source fluoxetine API from specialized manufacturers adhering to Good Manufacturing Practices (GMP) and regulatory standards such as U.S. FDA, EMA, or WHO certifications.


Global API Manufacturers for Fluoxetine Hydrochloride

1. Major API Suppliers

a. Teva Pharmaceutical Industries Ltd.

Teva is a leading Israeli pharmaceutical company with extensive expertise in producing generic APIs, including fluoxetine hydrochloride. Known for rigorous quality standards and global distribution channels, Teva supplies APIs to multiple generic and branded drug manufacturers worldwide.

b. Hetero Labs Limited

India-based Hetero is recognized for its robust portfolio of APIs and intermediates. It manufactures high-quality fluoxetine hydrochloride APIs, leveraging cost-effective production methods aligned with international standards—serving North American, European, and Asian markets.

c. Hubei Yitai Pharmaceutical Co., Ltd.

This Chinese manufacturer specializes in synthesizing and supplying fluoxetine APIs, primarily catering to Asian markets. Their facilities are GMP-compliant, with increasing recognition for quality among international clients.

d. Zhejiang Nanda Pharmaceutical Co., Ltd.

Zhejiang-based Nanda Pharmaceutical provides bulk fluoxetine hydrochloride to several generic drug manufacturers. Their focus on compliance with regulatory standards makes them a notable source.

e. Synthesis Partners and Contract Manufacturing Organizations (CMOs)

In addition to direct API suppliers, many pharmaceutical companies contract specialized CMOs for fluoxetine synthesis, offering customized manufacturing capacities aligned with client specifications.


2. Regional Focus and Diversification

North America & Europe

  • Concentrate on North American and European API suppliers like Teva, Camargo Pharmaceutical Services (via partnerships), and other GMP-certified manufacturers.
  • Regulatory barriers, such as FDA and EMA compliance, influence sourcing decisions.

Asia-Pacific

  • Countries like India and China dominate as API manufacturing hubs, offering competitive pricing and high-volume supply.
  • Key players include Hetero, Zheangjiang Nanda, and Hubei Yitai, leveraging cost advantages and large-scale production.

Procurement Considerations

1. Quality and Compliance

  • Prioritize suppliers with strict adherence to GMP, ISO certifications, and WHO prequalification.
  • Conduct supplier audits to evaluate quality control processes, API purity levels, and documentation records.

2. Regulatory Alignment

  • Ensure API suppliers comply with regional regulations, including U.S. FDA, EMA, and other markets.
  • Verify that API specifications match the approved drug formulation, including potency, residual solvents, and impurity profiles.

3. Supply Chain Reliability

  • Diversify sources among reputable manufacturers to mitigate risks of shortages.
  • Establish long-term supply agreements, considering geopolitical stability and manufacturing capacity scalability.

4. Cost and Lead Time

  • Balance cost efficiency with quality assurance; Indian API producers typically offer competitive prices.
  • Lead times depend on manufacturing capacity, certification, and shipping logistics.

Industry Trends in API Sourcing for Prozac Weekly

1. Increasing Regulatory Scrutiny

Global regulators enforce stringent quality controls, prompting pharmaceutical companies to verify supplier compliance before procurement. API sourcing strategies now increasingly incorporate supply chain transparency and documentation verification [1].

2. Shift Toward Regional Sourcing

While Asia remains dominant for cost-effective manufacturing, Western companies are diversifying sources to reduce dependency and enhance supply stability amid global disruptions such as the COVID-19 pandemic.

3. Biotech and Continuous Manufacturing

Emerging trends indicate a move toward continuous manufacturing methods, improving API purity and process efficiency, which may influence future sourcing approaches.

4. Environmental and Sustainability Considerations

Manufacturers adopting greener processes and sustainable practices are gaining favor, aligning with global regulatory expectations and corporate social responsibility commitments [2].


Regulatory and Quality Assurance in API Sourcing

Ensuring the API’s authenticity and purity involves compliance with rigorous standards. Regulatory authorities such as the U.S. FDA identify certified suppliers via inspections and documentation audits. Conversely, many Asian manufacturers seek prequalification to access Western markets, reinforcing adherence to international standards.

Pharmaceutical companies conduct due diligence, including:

  • Validating supplier GMP certifications
  • Reviewing audit reports
  • Performing batch testing and stability analysis
  • Maintaining supplier qualification dossiers

These efforts mitigate risks linked to counterfeit APIs, impurities, and quality lapses.


Conclusion

The sourcing landscape for fluoxetine hydrochloride API, essential for Prozac Weekly production, is diverse and regionally segmented. North American and European markets favor suppliers with stringent regulatory compliance, such as Teva and Camargo. Asian manufacturers, notably India and China-based firms like Hetero and Hubei Yitai, serve as robust alternative sources, offering cost advantages and high production capacity. Companies must weigh quality, regulatory compliance, supply reliability, and cost considerations when establishing procurement strategies.

Global supply chains are evolving to address challenges related to regulatory enforcement, geopolitical stability, and environmental sustainability. Balancing these factors ensures pharmaceutical manufacturers can maintain continuous supply, uphold product quality, and meet market demand for Prozac Weekly.


Key Takeaways

  • Diverse Supplier Base: The primary API sources for fluoxetine hydrochloride include reputable manufacturers from North America, Europe, and Asia, with India and China leading in volume and cost-efficiency.
  • Regulatory Compliance is Paramount: Suppliers must possess GMP, ISO, and WHO certifications to ensure API quality and facilitate market approval.
  • Supply Chain Resilience: Diversification of sourcing partners mitigates risks associated with geopolitical instability and manufacturing disruptions.
  • Emerging Industry Trends: Sustainability, continuous manufacturing, and stricter regulatory scrutiny influence procurement strategies.
  • Due Diligence Essential: Rigorous supplier qualification, testing, and documentation verification safeguard against counterfeit and substandard APIs.

FAQs

1. Who are the leading global manufacturers of fluoxetine hydrochloride API?
Leading manufacturers include Teva Pharmaceutical Industries (Israel), Hetero Labs (India), Hubei Yitai Pharmaceutical (China), and Zhejiang Nanda Pharmaceutical (China), among others.

2. What are key quality considerations when sourcing API for Prozac Weekly?
Compliance with GMP standards, regulatory certifications, API purity, impurity profile, consistent batch quality, and documentation are critical.

3. How does regional sourcing impact API procurement?
North American and European sources typically emphasize regulatory compliance and quality, while Asian sources offer cost advantages and higher manufacturing capacity but require rigorous qualification to ensure compliance.

4. Are there sustainability practices among API manufacturers?
Yes, some manufacturers adopt green chemistry, reduced waste, and energy-efficient processes, aligning with global sustainability directives.

5. What future trends will shape API sourcing for Prozac Weekly?
Emerging trends include increased regulatory scrutiny, diversification to regional suppliers, adoption of biotech manufacturing techniques, and a focus on sustainability.


References

[1] U.S. Food and Drug Administration. "Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients." 2021.
[2] World Health Organization. "Prequalification of Medicines Programme." 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.